美国国家肺癌筛查试验中磨玻璃影管理启示
基于美国国家肺癌筛查试验(NLST),按直径计算磨玻璃影(GGO)与实性结节的恶性概率,并以实性结节恶性风险为基准提出GGO风险分层管理类别,同时比较同一风险类别下GGO与实性结节的肺癌死亡率。
要点
- 同一Lung-RADS v1.0类别内,GGO的恶性概率高于实性结节。
- 按恶性概率分层,4-5 mm GGO年度筛查(恶性风险0.4%),6-7 mm(1.1%)、8-14 mm(3.0%)、15-19 mm(5.2%)6个月随访,≥20 mm(10.9%)3个月随访。
- 6个月随访类别中GGO肺癌死亡率低于实性结节(HR=0.18,95%CI:0.05-0.67)。
核心结论
- 若Lung-RADS的GGO类别基于恶性概率,则6-19 mm GGO应接受6个月随访,≥20 mm GGO应接受3个月随访。
- 这种基于风险的GGO管理可提高Lung-RADS的敏感性,尤其对大的GGO肺癌。
- 然而,小的GGO肺癌侵袭性低于实性结节 counterparts。
研究设计与样本
- 基于美国国家肺癌筛查试验(NLST)的分析。
- 计算NLST中GGO与实性结节的直径特异性恶性概率。
- 以实性结节恶性风险为基准,提出GGO基于恶性概率的风险管理类别。
- 比较同一风险类别下GGO与实性结节的肺癌死亡率。
主要发现
- 使用Lung-RADS v1.0分类,同一类别内GGO的恶性概率高于实性结节。
- 按风险分类,4-5 mm GGO年度筛查,恶性风险0.4%。
- 6-7 mm GGO 6个月随访,恶性风险1.1%;8-14 mm为3.0%;15-19 mm为5.2%。
- ≥20 mm GGO 3个月随访,恶性风险10.9%。
- 重新分类后,3个月随访类别中GGO与实性结节肺癌死亡的HR=2.0(95%CI:0.4-8.7);6个月随访类别中GGO肺癌死亡率更低,HR=0.18(95%CI:0.05-0.67)。
关键数值与推荐
- Lung-RADS建议直径小于20 mm的GGO年度筛查,直径大于等于20 mm的GGO接受6个月随访。
- 基于恶性概率的风险分类:4-5 mm GGO年度筛查(0.4%);6-7 mm(1.1%)、8-14 mm(3.0%)、15-19 mm(5.2%)6个月随访;≥20 mm(10.9%)3个月随访。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In the National Lung Screening Trial (NLST), screen-detected cancers that would not have been identified by the Lung Computed Tomographic Screening Reporting and Data System (Lung-RADS) nodule management guidelines were frequently ground-glass opacities (GGOs). Lung-RADS suggests that GGOs with diameter less than 20 mm return for annual screening, and GGOs greater than or equal to 20 mm receive 6-month follow-up. We examined whether this 20-mm threshold gives consistent management of GGOs compared with solid nodules. METHODS: First, we calculated diameter-specific malignancy probabilities for GGOs and solid nodules in the NLST. Using the solid-nodule malignancy risks as benchmarks, we suggested risk-based management categories for GGOs based on their probability of malignancy. Second, we compared lung-cancer mortality between GGOs and solid nodules in the same risk-based category. RESULTS: Using the Lung-RADS v1.0 classifications, malignancy probability is higher for GGOs than solid nodules within the same category. A risk-based classification of GGOs would assign annual screening for GGOs 4 to 5 mm (0.4% malignancy risk); 6-month follow-up for GGOs 6 to 7 mm (1.1%), 8 to 14 mm (3.0%), and 15 to 19 mm (5.2%); and 3-month follow-up for greater than or equal to 20 mm (10.9%). This reclassification would have assigned similarly fatal cancers to 3-month follow-up (hazard ratio = 2.0 for lung-cancer death in GGOs versus solid-nodule cancers, 95% confidence interval: 0.4-8.7), but for 6-month follow-up, mortality was lower in GGO cancers (hazard ratio = 0.18, 95% confidence interval: 0.05-0.67). CONCLUSIONS: If Lung-RADS categories for GGOs were based on malignancy probability, then 6- to 19-mm GGOs would receive 6-month follow-up and greater than or equal to 20-mm GGOs would receive 3-month follow-up. Such risk-based management for GGOs could improve the sensitivity of Lung-RADS, especially for large GGO cancers. However, small GGO cancers were less aggressive than their solid-nodule counterparts.
引用
- Robbins HA, Katki HA, Cheung LC, et al. Insights for Management of Ground-Glass Opacities From the National Lung Screening Trial. J Thorac Oncol. 2019. PMID: 31125735. doi:10.1016/j.jtho.2019.05.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。